| Name | (2S)-2-N,2-N-dimethyl-1-N-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]pyrrolidine-1,2-dicarboxamide |
|---|---|
| Synonyms |
1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide
UNII-VX2GBO4I0V Fedovapagon Fedovapagon [INN] (2S)-N2,N2-dimethyl-N1-((2-Methyl-4-(2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)phenyl)methyl)pyrrolidine-1,2-dicarboxamide (2S)-N(sup 2),N(sup 2)-Dimethyl-N(sup 1)-((2-methyl-4-(2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)phenyl)methyl)pyrrolidine-1,2-dicarboxamide |
| Description | Fedovapagon is a selective vasopressin V2 receptor (V2R) agonist with an EC50 of 24 nM, which is being developed for the treatment of nocturia[1]. |
|---|---|
| Related Catalog | |
| Target |
EC50:24 nM (V2R)[1] |
| References |
| Molecular Formula | C27H34N4O3 |
|---|---|
| Molecular Weight | 462.58400 |
| Exact Mass | 462.26300 |
| PSA | 76.45000 |
| LogP | 3.94760 |